
Tectonic Therapeutic, Inc. is a biotechnology company. The Company is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Leveraging its technology platform called GEODe (GPCRs Engineered for Optimal Disco... Tectonic Therapeutic, Inc. is a biotechnology company. The Company is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Leveraging its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), the Company is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. The Company's lead program, TX000045 (TX45), is an Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. TX45 is being evaluated in Phase Ia/Ib clinical trials as a potential treatment for Group 2 Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (HFpEF). Its second program addresses Hereditary Hemorrhagic Telangiectasia (HHT). 詳細を表示
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.51 | -2.20683686716 | 23.11 | 24.21 | 21.13 | 201109 | 22.97686782 | CS |
4 | -10.82 | -32.3758228606 | 33.42 | 36.11 | 21.13 | 267529 | 28.53118998 | CS |
12 | -21.22 | -48.4253765404 | 43.82 | 61.07 | 15.3 | 339486 | 41.64023269 | CS |
26 | 5.1 | 29.1428571429 | 17.5 | 61.07 | 15.3 | 221187 | 39.86696125 | CS |
52 | 5.7 | 33.7278106509 | 16.9 | 61.07 | 15.0001 | 160407 | 38.60591894 | CS |
156 | 5.7 | 33.7278106509 | 16.9 | 61.07 | 15.0001 | 160407 | 38.60591894 | CS |
260 | 5.7 | 33.7278106509 | 16.9 | 61.07 | 15.0001 | 160407 | 38.60591894 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約